Association of the 8473t>C Cyclooxygenase-2 (COX-2) gene polymorphism with lung cancer risk in Asians

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 5, 2010, Pages 1257-1262

  Liu, Fen ^a   He, Yan ^a   Peng, Xiaoxia ^a   Wang, Wei ^a   Yang, Xinghua ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Lung cancer; Meta analysis; Molecular epidemiology; Polymorphism

Indexed keywords

EID: 79955949312     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Campa D, Hung RJ, Mates D, et al. (2005). Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 14, 538-9.
2. Campa D, Zienolddiny S, Maggini V, et al. (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229-35.
3. Castelao JE, Bart RD 3rd, Di Perna CA, Sievers EM, Bremner RM. (2003). Lung cancer and cyclooxygenase-2. Ann Thorac Surg, 76, 1327-35.
4. DeBruin LS, Josephy PD. (2002). Perspectives on the chemical etiology of breast cancer. Environ Hlth Perspect, 110, 119-28.
5. Egger M, Smith GD, Schneider M, et al. (1997). Bias in metaanalysis detected by a simple graphical test. BMJ, 315, 629-34.
6. Gou Q, Liu CH, Ben-Av P, et al. (1998). Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3'-untranslated region. Biochem Biophys Res Commun, 242, 508-12.
7. Harris RE, Beebe-Donk J, Doss H, et al. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep, 13, 559-83.
8. Herschman H. (1996). Prostaglandin synthase 2. Biochim Biophys Acta, 1299, 125-40.
9. Higgins JP, Thompson SG, Deeks JJ, et al. (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
10. Hla T, Bishop-Bailey D, Liu CH, et al. (1999). Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol, 31, 551-7.
11. Hu Z, Miao X, Ma H, et al. (2005). A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer, 48, 11-7.
12. Jacobs EJ, Thun MJ, Bain EB, et al. (2007). A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst, 99, 608-15.
13. Kang S, Kim YB, Kim MH, et al. (2005). Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett, 217, 11-6.
14. Langsenlehner U, Yazdani-Biuki B, Eder T, et al. (2006). The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res, 12, 1392-4.
15. Lau J, Ioannidis JP, Schmid CH. (1997). Quantitative synthesis in systematic reviews. Ann Intern Med, 127, 820-6.
16. Lee TS, Jeon YT, Kim JW, et al. (2007). Lack of association of the cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphism with risk of cervical cancer in Korean population. Ann N Y Acad Sci, 1095, 134-42.
17. Lira MG, Mazzola S, Tessari G, et al. (2007). Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. Br J Dermatol, 157, 49-57.
18. Liu CJ, Hsia TC, Wang RF, et al. (2010). Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res, 30, 1195-9.
19. Park JM, Choi1 JE, Chae MH, et al. (2006). Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer, 6, 70.
20. Parkin DM. (2001). Globocal cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
21. Pereira C, Medeiros RM, Dinis-Ribeiro MJ. (2009). Cyclooxygenase polymorphisms in gastric and colorectal carcinogenesis: are conclusive results available? Eur J Gastroenterol Hepatol, 21, 76-91.
22. Petitti DB. (1994). Meta-analysis, decision analysis and cost-effectiveness analysis. In 'Statistical methods in meta-analysis', Eds Petitti DB. Oxford University Press, New York, NY, 90-114.
23. Sakoda LC, Gao YT, Chen BE, et al. (2006). Prostaglandinendoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis, 27, 1251-6.
24. Sanak M, Szczeklik W, Szczeklik A. (2005). Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma. J Allergy Clin Immunol, 116, 221-3.
25. Shahedi K, Lindstrom S, Zheng SL, et al. (2006). Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer, 119, 668-72.
26. Shields PG. (2002). Molecular epidemiology of smoking and lung cancer. Oncogene, 21, 6870-6.
27. Siemes C, Visser LE, Coebergh JW, et al. (2008). Protective effect of NSAIDs on cancer and influence of COX-2 C (-765G) genotype. Curr Cancer Drug Targets, 8, 753-64.
28. Sørensen M, Autrup H, Tjønneland A, et al. (2005). A genetic polymorphism in prostaglandin synthase 2 (8473, T-C) and the risk of lung cancer. Cancer Lett, 226, 49-54.
29. Stroup DF, Berlin JA, Morton SC, et al. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA, 283, 2008-12.
30. Takkouche B, Regueira-Méndez C, Etminan M. (2008). Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst, 100, 1439-47.
31. Thun MJ, Henley SJ, Patrono C. (2002). Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 94, 252-66.
32. Thun MJ, Namboodiri MM, Heath CW Jr. (1991). Aspirin use and reduced risk of fatal colon cancer. N Engl J Med, 325, 1593-6.
33. Vogel U, Christensen J, Wallin H, et al. (2008). Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res, 639, 89-100.
34. Wolff H, Saukkonen K, Anttila S, et al. (1998). Expression of Cyclooxygenase-2 in human lung carcinoma. Cancer Res, 58, 4997-5001.
35. Wright JL, Hobson JE, Wiggs B, et al. (1988). Airway inflammation and peribronchiolar attachments in the lungs of nonsmokers, current and ex-smokers. Lung, 166, 277-86.
36. Zhu W, Wei BB, Shan X, Liu P. (2010). -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case-control studies. Mol Biol Rep, 37, 277-88.